Eastgate Biotech (ETBI) 10-Q 23 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 23, 2015
Document and Entity Information:
Entity Registrant Name	EASTGATE BIOTECH CORP
Entity Central Index Key	1,099,574
Trading Symbol	etbi
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		290,872,175
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current
Cash		$ 286,481
Accounts Receivable	$ 35,993
Deposits	55,333
Sales tax recoverable	75,465	53,208
Total current assets	166,791	339,689
Other assets
Property & Equipment, net	197,954	143,246
Total other assets	197,954	143,246
Total assets	364,745	482,935
Current liabilities
Bank indebtedness	5,948
Accounts payable and accrued liabilities	337,359	299,099
Accrued liabilities related party	215,178	388,675
Deferred rent	2,512	4,200
Capital lease obligation - Current Portion	7,621
Accrued interest - related parties	261,647	182,845
Notes payable - related parties	1,278,120	1,006,391
Total current liabilities	2,108,385	1,881,210
Long term liabilities
Capital lease obligation - long term	52,650
Total long term liabilities	52,650
Total Liabilities	$ 2,161,035	$ 1,881,210
Stockholders' equity (deficit) Authorized:
Preferred stock:50,000,000 shares authorized at $0.00001 par value no shares issued at September 30, 2015 and December 31, 2014
Common stock: 450,000,000 shares authorized at $0.00001 par value 290,662,175 and 89,635,234 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 2,907	$ 896
Additional paid-in capital	9,003,626	5,957,771
Accumulated other comprehensive income	25,062	15,268
Accumulated deficit	(10,827,885)	(7,372,210)
Total stockholders' Equity (Deficit)	(1,796,290)	(1,398,275)
Total liabilities and stockholders' equity (deficit)	$ 364,745	$ 482,935

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Common stock, shares authorized	450,000,000	450,000,000
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, issued	290,662,175	89,635,234
Common stock, outstanding	290,662,175	89,635,234

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
REVENUES	$ 73,179		$ 131,722
Cost of goods sold	11,059		19,489
Gross profit	62,120		112,233
OPERATING EXPENSES
Professional fees	26,757	$ 22,943	123,960	$ 125,941
Research & development	257,380	308,044	951,358	693,535
General and administrative	464,756	575,604	1,974,458	2,904,319
Marketing and selling	119,594	23,526	439,330	58,330
Total Operating Expenses	868,487	930,117	3,489,106	3,782,125
LOSS FROM OPERATIONS	(806,367)	(930,117)	(3,376,873)	(3,782,125)
Other items
Interest expense	(29,449)	(23,112)	(78,802)	(68,047)
Total other items	(29,449)	(23,112)	(78,802)	(68,047)
LOSS BEFORE INCOME TAXES	$ (835,816)	$ (953,229)	$ (3,455,675)	$ (3,850,172)
PROVISION FOR INCOME TAXES
NET LOSS	$ (835,816)	$ (953,229)	$ (3,455,675)	$ (3,850,172)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	$ 0	$ (0.02)	$ (0.02)	$ (0.09)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED (in shares)	217,302,267	50,204,563	161,087,899	42,974,824
COMPREHENSIVE LOSS A summary of the components of other comprehensive loss for the periods ended as follows:
Net Loss	$ (835,816)	$ (953,229)	$ (3,455,675)	$ (3,850,172)
Other Comprehensive Loss - foreign currency translation	15,107	(4,497)	9,794	12,649
Comprehensive Loss	$ (820,709)	$ (957,726)	$ (3,445,881)	$ (3,837,523)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (3,455,675)	$ (3,850,172)
Adjustments to reconcile net loss to net cash used by operating activities:
Expenses paid on the Company's behalf by a related party		4,938
Common stock issued for services	1,413,109	1,263,911
Depreciation	30,693	18,723
Stock options issued	291,427
Changes in operating assets and liabilities:
Accrued interest	78,802	46,920
Prepaid asset	(55,333)	(40,242)
Accounts payable	67,498	(92,294)
Accounts Receivable	(38,392)
Accrued liabilities related party	1,150,291	1,517,962
Sales tax recoverable	(31,283)	(40,546)
Deferred rent	(1,206)
Cash flows used in operating activities	(550,069)	(1,170,800)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(95,903)
Cash flows used in investing activities		(95,903)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of capital lease obligation	(4,130)	(24,380)
Proceeds from notes payable related party	280,624	125,808
Payments on notes payable related party	(5,536)	(48,166)
Common stock issued for cash	5,000	1,206,500
Net proceeds from Bank indebtedness	6,345
Cash flows provided by financing activities	282,303	1,259,762
NET INCREASE (DECREASE) IN CASH	(267,766)	(6,941)
Effect of foreign currency translation adjustments	(18,715)	12,649
Cash, beginning of the period	$ 286,481	458
Cash, end of the period		$ 6,166
Supplemental disclosures of cash flow information:
Cash paid for income taxes
Cash paid for interest	$ 1,261	$ 20,151
Non Cash Financing activities:
Common stock issued to convert liabilities	1,317,330	2,025,876
Common stock issued - subscription payable		$ 2,000
Equipment Purchased for Capital lease obligation And Common Stock	85,401
Employee Advance repaid for reduction of Notes payable Related Party	$ 3,359

CONDENSED FINANCIAL STATEMENTS

CONDENSED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED FINANCIAL STATEMENTS	NOTE 1 - CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Eastgate Biotech Corp without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2015, and for all periods presented herein have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2014 audited financial statements. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of the operating results for the full years.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2015
Going Concern [Abstract]
GOING CONCERN	NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has accumulated deficit of $10,827,885 as of September 30, 2015. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary Eastgate Pharmaceuticals Inc. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Research and Development Costs The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration. Foreign Currency Translation Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity. Recent Accounting Pronouncements In August 2014, FASB issued ASU No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements – Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU. However, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure. In April 2015 the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03 to simplify the presentation of debt issuance costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts and premiums. The ASU also requires that the amortization of debt issuance costs be reported as interest expense. For public companies, this ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015 (early adoption is permitted). The adoption of this ASU will impact the presentation of the Company’s financial statements in future periods should it be successful in raising funds. In April 2015, the FASB issued ASU 2015-05 related to customer’s accounting for fees paid in a cloud computing arrangement. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015 (early adoption is permitted). The Company does not expect this ASU to have a significant impact on its consolidated financial position, results of operations or cash flows. The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company's financial position or statements.

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE 4 –RELATED-PARTY TRANSACTIONS Notes payable – related parties The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand.

SALES TAX RECOVERABLE

SALES TAX RECOVERABLE	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Sales tax recoverable	NOTE 5 –SALES TAX RECOVERABLE Sales tax receivable The Company recovers sales tax paid, for which returns are filed on annual basis. At September 30, 2015, $75,465 was claimed as recoverable compared to the December 31, 2014 balance of $53,208. Sales tax recoverable is a result of sales tax paid on eligible expenses.

PROPERTY & EQUIPMENT AND CAPITA

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION	NOTE 6 – PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION On August 21, 2015 the Company entered into a capital lease agreement to purchase equipment. The lease had a term of 60 months starting August 21, 2015 with the final payment due on June 21, 2020. The lease specified a monthly rate of $1,797. The lease required minimum lease payments of $107,822 over the term of the lease and recorded at $64,401, which is the present value of the minimum lease payments (less no executor cost) using the effective interest rate of 24.46%. During the nine month ended September 30, 2015 the Company paid principal of $4,130 against the capital lease obligation and corresponding interest of $1,261, leaving an amount owing at the end of the period of $60,271, $52,650 of which is a long-term obligation. The equipment was purchased for $85,401, comprisied of $64,401 in lease payments and $21,000 in stock issued at $0.014 per share, or 1,500,000 common shares.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7 – STOCKHOLDERS' EQUITY On January 5, 2015, the Company issued 8,146,225 Units of its securities in satisfaction of accrued liabilities comprised of $325,849 of compensation owed to eight directors and members of management at the price of $0.04 per share. Each Unit consisted of one share of common stock and a five year warrant to purchase one share of common stock at an exercise price of $0.04 per share. As a result of this transaction, the Company issued 8,146,225 shares of common stock and 8,146,225 warrants to purchase our common stock. In January 2015, the Company issued a total of 3,700,000 shares of common stock to consultants for services rendered at the price of $0.035 per share. On February 12, 2015, the Company issued a total of 15,250,000 shares of common stock to employees and consultants for services rendered at the price of $0.0286 per share. In March 2015, the Company issued a total of 8,683,333 shares of common stock to consultants for services rendered at the price of $0.033 per share. During the quarter ended March 31, 2015, the Company issued a total of 977,233 shares of common stock to consultants for services rendered at the price ranging from $0.06 to $0.50 per share. During the quarter ended March 31, 2015, the Company issued 1,770,346 shares of common stock to two officers and an employee as part of their compensation at the price of $0.055 per share. On May 22, 2015, the Company issued 62,285,718 shares of common stock in satisfaction of accrued liabilities comprised of $436,000 of compensation owed to the eight who are directors, officers and members of management at the market price of $0.007 per share. On June19, 2015, the Company issued 15,000,000 shares of common stock to a director and two officers in recognition of the progress made in the development platform being used in various pharmaceutical and natural products. The shares were issued at the price of $0.0149 per shares. On August 21, 2015 the Company sold 125,000 Units at a purchase price of $0.04 per Unit in a private placement of its securities to accredited investors for total proceeds of $5,000. Each Unit consisted of one share of common stock and a five year warrant to purchase one share at an exercise price of $0.04 per share. On August 21, 2015 the Company issued 870,000 shares of common stock to a consultant for services at a price of $0.014 per share. On August 25, 2015, The Company issued 1,500,000 shares at closing price of $0.014 as a partial payment for acquisition of equipment (see Note 6). On September 18, 2015, the Company awarded the issue 5,000,000 shares of common stock to a director and officer for services valued at $50,000 in the natural product division. The shares were issued at the price of $0.01 per shares. On September 18, 2015, the Company issued 17,000,000 shares of common stock to two officers and one employee as part of their annual compensation at the price of $0.01 per shares. On September 18, 2015, the Company issued 55,466,665 shares of common stock in satisfaction of accrued liabilities comprised of $554,667 of compensation owed to the eight who are directors, officers and members of management at the market price of $0.01 per share. On September 21, 2015 the Company issued 8,000,000 shares of common stock to consultants for services at a price of $0.013 per share. As of December 31, 2014, the Company had 17,272,300 warrants to purchase common stock. During the period ended September 30, 2015 the Company issued an additional 8,271,225 warrants. All outstanding warrants have a weighted average price of $0.11 per share and have a weighted average remaining life of 4.25 years. The following table summarizes warrants that are issued, outstanding and exercisable Warrants Issued & Outstanding Exercise Expiration September 30 December 31 Price Date 2015 2014 $ 0.25 March 14, 2019 3,495,000 3,495,000 $ 0.25 March 21, 2019 3,480,000 3,480,000 $ 0.25 June 6, 2019 2,022,300 2,022,300 $ 0.05 October 16, 2019 150,000 150,000 $ 0.04 December 31, 2019 8,125,000 8,125,000 $ 0.04 January 5 , 2020 8,146,225 - $ 0.04 August 17, 2020 125,000 - 25,543,525 17,272,300 Stock Options On February 12, 2015 the Company issued a total of 10,375,000 options to purchase shares of common stock to employees and consultants as compensation at an exercise price of $0.0286 per share. The fair value was estimated using the Black-Scholes option pricing model, taking into account the grant date exercise price of $0.0286, an expected life of the option of 2.5 years, an expected volatility of 211.1%, expected dividends on the stock of 0 and the risk-free interest rate for the term of the option of 1.02%. The total fair value of the options at the date of the grant was $291,427. The options vested immediately and compensation expense of $291,427 was recorded on the grant date. The following table summarizes the stock options that are issued, outstanding and exercisable Stock Options Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2015 2014 $ 0.286 February 12, 2020 10 0

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8– SUBSEQUENT EVENTS In accordance with ASC 855 Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report except as described below: On October 5, 2015 the Company sold 200,000 common shares at a price of $0.10 per share in a private placement of its securities to accredited investors for total proceeds of $20,000. Associated with this transaction is another 10,000 common shares in finders fees. On October 7, 2015 the Company signed an agreement with Andrew Garrett Inc. as financial advisor and placement agent in connection with a private placement of unregistered securities of up to $20 million. Upon signing this agreement the Company issued Andrew Garrett Inc. a fee of 16,171,627 warrants to purchase common stock of the corporation at $0.00001 per common share. The warrants expire in 5 years.

SIGNIFICANT ACCOUNTING POLICI14

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary Eastgate Pharmaceuticals Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
Foreign Currency Translation	Foreign Currency Translation Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, FASB issued ASU No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements – Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU. However, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure. In April 2015 the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03 to simplify the presentation of debt issuance costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts and premiums. The ASU also requires that the amortization of debt issuance costs be reported as interest expense. For public companies, this ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015 (early adoption is permitted). The adoption of this ASU will impact the presentation of the Company’s financial statements in future periods should it be successful in raising funds. In April 2015, the FASB issued ASU 2015-05 related to customer’s accounting for fees paid in a cloud computing arrangement. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015 (early adoption is permitted). The Company does not expect this ASU to have a significant impact on its consolidated financial position, results of operations or cash flows. The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company's financial position or statements.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of summarizes warrants that are issued, outstanding and exercisable	Warrants Issued & Outstanding Exercise Expiration September 30 December 31 Price Date 2015 2014 $ 0.25 March 14, 2019 3,495,000 3,495,000 $ 0.25 March 21, 2019 3,480,000 3,480,000 $ 0.25 June 6, 2019 2,022,300 2,022,300 $ 0.05 October 16, 2019 150,000 150,000 $ 0.04 December 31, 2019 8,125,000 8,125,000 $ 0.04 January 5 , 2020 8,146,225 - $ 0.04 August 17, 2020 125,000 - 25,543,525 17,272,300
Schedule of stock options that are issued, outstanding and exercisable	Stock Options Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2015 2014 $ 0.286 February 12, 2020 10 0

GOING CONCERN (Detail Textuals)

GOING CONCERN (Detail Textuals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Going Concern [Abstract]
Accumulated deficit	$ (10,827,885)	$ (7,372,210)

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Detail Textuals) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Accrued interest to related parties	$ 261,647	$ 182,845
Notes payable - related parties
Related Party Transaction [Line Items]
Percentage of interest rates on notes payable - related parties, minimum	5.00%
Percentage of interest rates on notes payable - related parties, maximum	10.00%
Advanced cash received by related party shareholder	$ 280,624	190,880
Expenses paid by company on behalf of related party	3,359	4,938
Repayment of related party loans	5,536
Accrued interest to related parties	261,646	182,845
Interest expense	$ 78,802	$ 88,879

SALES TAX RECOVERABLE (Detail T

SALES TAX RECOVERABLE (Detail Textuals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Sales tax recoverable	$ 75,465	$ 53,208

PROPERTY & EQUIPMENT AND CAPI19

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION (Detail Textuals) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 21, 2015	Sep. 30, 2015	Aug. 25, 2015
Property, Plant and Equipment [Line Items]
Equipment purchased for capital lease obligation		$ 85,401
Price per share			$ 0.014
Capital Lease Obligations
Property, Plant and Equipment [Line Items]
Capital lease agreement term	60 months
Lease agreement monthly rate amount	$ 1,797
Minimum lease payment amount	107,822
Minimum lease payments	$ 64,401
Effective interest rate of lease payments	24.46%
Principal amount of capital lease obligation		4,130
Interest amount of capital lease obligation		1,261
Amount owing at the end of period		60,271
Long-term obligation		52,650
Equipment purchased for capital lease obligation		85,401
Value of stock issued		$ 21,000
Price per share		$ 0.014
Number of common shares issued		1,500,000

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of warrants issued, outstanding and exercisable (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Warrants Issued & Outstanding	25,543,525	17,272,300
March 14, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.25	$ 0.25
Expiration Date	Mar. 14, 2019	Mar. 14, 2019
Warrants Issued & Outstanding	3,495,000	3,495,000
March 21, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.25	$ 0.25
Expiration Date	Mar. 21, 2019	Mar. 21, 2019
Warrants Issued & Outstanding	3,480,000	3,480,000
June 6, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.25	$ 0.25
Expiration Date	Jun. 6, 2019	Jun. 6, 2019
Warrants Issued & Outstanding	2,022,300	2,022,300
October 16, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.05	$ 0.05
Expiration Date	Oct. 16, 2019	Oct. 16, 2019
Warrants Issued & Outstanding	150,000	150,000
December 31, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.04	$ 0.04
Expiration Date	Dec. 31, 2019	Dec. 31, 2019
Warrants Issued & Outstanding	8,125,000	8,125,000
January 5, 2020
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.04	$ 0.04
Expiration Date	Jan. 5, 2020	Jan. 5, 2020
Warrants Issued & Outstanding	8,146,225
August 17, 2020
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.04	$ 0.04
Expiration Date	Aug. 17, 2020	Aug. 17, 2020
Warrants Issued & Outstanding	125,000

STOCKHOLDERS' EQUITY - Summar21

STOCKHOLDERS' EQUITY - Summary of stock options issued, outstanding and exercisable (Details 1) - Employee Stock Option - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.286	$ 0.286
Expiration Date	Feb. 12, 2020	Feb. 12, 2020
Stock Options Issued & Outstanding (in shares)	10,375,000	0

STOCKHOLDERS' EQUITY (Detail Te

STOCKHOLDERS' EQUITY (Detail Textuals)	Feb. 12, 2015USD ($)$ / sharesshares	Jan. 05, 2015USD ($)Director$ / CommonStock_Warrantshares	Sep. 21, 2015$ / sharesshares	Sep. 18, 2015USD ($)OfficerDirector$ / sharesshares	Aug. 25, 2015$ / sharesshares	Aug. 21, 2015USD ($)$ / shares$ / CommonStock_Warrantshares	Jun. 19, 2015Officer$ / sharesshares	May. 22, 2015USD ($)Director$ / sharesshares	Mar. 31, 2015Officer$ / sharesshares	Jan. 31, 2015$ / sharesshares	Mar. 31, 2015Officer$ / sharesshares	Sep. 30, 2015shares	Dec. 31, 2014$ / sharesshares
Stockholders Equity Note [Line Items]
Weighted average life													4 years 3 months
Number of warrants to purchase common stock													17,272,300
Shares issued for services rendered (in shares)					1,500,000
Price per share | $ / shares					$ 0.014
Exercise price | $ / shares													$ 0.11
Number of warrants issued												8,271,225
Employee Stock Option
Stockholders Equity Note [Line Items]
Options issue to purchase shares of common stock												10,375,000	0
Accredited investors
Stockholders Equity Note [Line Items]
Units issue price | $ / CommonStock_Warrant						0.04
Number of common stock in each unit						1
Weighted average life						5 years
Issued shares of common stock						125,000
Price per share | $ / shares						$ 0.04
Number of private placement units sold						125,000
Proceeds from issuance of private placement | $						$ 5,000
Employee and Consultant
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)	15,250,000
Price per share | $ / shares	$ 0.0286
Employee and Consultant | Employee Stock Option
Stockholders Equity Note [Line Items]
Options issue to purchase shares of common stock	10,375,000
Total fair value of options at the date of the grant | $	$ 291,427
Pricing model	Black-Scholes option pricing model
Exercise price | $ / shares	$ 0.0286
Expected life of option	2 years 6 months
Expected volatility	211.10%
Expected dividends | $	$ 0
Risk-free interest rate	1.02%
Consultant
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)									8,683,333	3,700,000	977,233
Price per share | $ / shares									$ 0.033	$ 0.035	$ 0.033
Consultant | Minimum
Stockholders Equity Note [Line Items]
Price per share | $ / shares									0.06		0.06
Consultant | Maximum
Stockholders Equity Note [Line Items]
Price per share | $ / shares									0.50		$ 0.50
Officers
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)				17,000,000							1,770,346
Price per share | $ / shares				$ 0.01					$ 0.055		$ 0.055
Entity Number of Employees | Officer				2					2		2
Common stock and warrant unit
Stockholders Equity Note [Line Items]
Number of units issued		8,146,225
Proceeds from issuance of warrants | $		$ 325,849
Number of directors and members | Director		8
Units issue price | $ / CommonStock_Warrant		0.04
Number of common stock in each unit		1
Weighted average life		5 years
Issued shares of common stock		8,146,225
Number of warrants to purchase common stock		8,146,225
Common stock
Stockholders Equity Note [Line Items]
Proceeds from issuance of warrants | $				$ 554,667				$ 436,000
Number of directors and members | Director				8				8
Shares issued for services rendered (in shares)				55,466,665			15,000,000	62,285,718
Price per share | $ / shares				$ 0.01			$ 0.0149	$ 0.007
Entity Number of Employees | Officer							2
Common stock | Consultant
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)			8,000,000			870,000
Price per share | $ / shares			$ 0.013			$ 0.014
Common stock | Officers
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)				5,000,000
Price per share | $ / shares				$ 0.01
Value of shares issued | $				$ 50,000

SUBSEQUENT EVENTS (Detail Textu

SUBSEQUENT EVENTS (Detail Textuals) - USD ($)	Oct. 07, 2015	Oct. 05, 2015	Aug. 25, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Shares issued, price per share (in dollars per share)			$ 0.014
Number of warrants to purchase common stock				17,272,300
Subsequent event
Subsequent Event [Line Items]
Common shares issued in finders fees		$ 10,000
Subsequent event | Andrew Garrett Inc.
Subsequent Event [Line Items]
Maximum threshold limit of private placement of unregistered securities	$ 20,000,000
Subsequent event | Andrew Garrett Inc. | Warrants
Subsequent Event [Line Items]
Number of warrants to purchase common stock	16,171,627
Exercise price (in dollars per share)	$ 0.00001
Expiration period of warrants	5 years
Subsequent event | Accredited investors
Subsequent Event [Line Items]
Stock issued, Shares		200,000
Shares issued, price per share (in dollars per share)		$ 0.10
Value of common shares sold in private placement		$ 20,000